When developing new generic medicines, pharmaceutical companies need to ensure their products are as effective and safe as existing drugs. To achieve this, they use Reference Listed Drugs (RLDs) as benchmarks. Reliable sourcing and procurement of these RLDs are crucial for maintaining the quality of new medications. Here’s a simple guide to understanding how this process works and the role of Ikris Pharma Network (IPN) in this field.

What are Reference Listed Drugs (RLDs)?
Reference Listed Drugs (RLDs) are brand-name drugs used as standards for comparing new generic versions. When a company wants to develop a generic drug, it must prove that its product performs similarly to the original RLD. This comparison ensures that the new drug is both effective and safe for patients.

Why is Reliable Sourcing Important?
Reliable sourcing of Reference Listed Drugs (RLDs) is essential for several reasons:

• Ensuring Quality: The new generic drug must meet the same quality standards as the RLD. Reliable sourcing ensures that the RLD used for comparison is authentic and of high quality.
• Regulatory Compliance: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), require that new generics demonstrate equivalence to RLDs. Accurate sourcing helps companies meet these regulatory requirements.
• Clinical Trials: In clinical trials, RLDs are used to test the performance of new drugs. Reliable sourcing ensures that the RLDs used in these trials are correct, helping to validate the new drug’s effectiveness.

Sourcing RLDs Globally: Ikris Pharma Network (IPN):
To guarantee the highest quality of reference drugs, companies often need to procure reference-listed drugs (RLDs) from various regions worldwide. With warehouse facilities strategically located in Bulgaria and Belgium, we can rapidly and readily move medicinal products around the world. 
From the start of the procurement process to the final delivery to our customers, Ikris Pharma Network (IPN) follows a robust/comprehensive set of global Standard Operating Procedures (SOPs) and industry guidelines, ensuring that all processes maintain the highest standards of quality. We forge strategic alliances with reliable reference-listed drugs/RLD Suppliers in Turkey, Australia, France, Belgium, Brazil, Bulgaria, etc to access high-quality Reference-listed Drugs (RLDs).

Countries We Can Source From: Here’s how reliable sourcing can be managed in various parts of the world: Brazil, India, China, Italy, Spain, Netherlands, Switzerland, Singapore, Ireland, Sweden, Belgium, France, Turkey, Australia, United States, United Kingdom, Germany, Canada, Japan, and South Korea.

Reliable Sourcing of Reference-listed Drugs (RLDs) with IPN:
Ikris Pharma Network (IPN) is a leading provider/facilitator of reference-listed drugs globally. We have a well-established network of validated RLD suppliers in France and other key regions across the world. Our global presence allows us to source high-quality RLDs efficiently and securely.

As your trusted clinical trial supplier, IPN ensures that you receive authentic and reliable RLDs for your drug development needs. Our extensive experience and strong relationships with suppliers in various regions enable us to provide timely and accurate sourcing solutions. Whether you need RLDs from Europe, the Middle East, or other parts of the world, IPN is equipped to meet your needs.

Ikris works closely with trusted RLD suppliers in Belgium/Bulgaria to ensure easy access to high-quality Reference-listed Drugs (RLDs) that meet strict regulatory standards. These strong partnerships allow Ikris to consistently provide top-quality RLDs to pharmaceutical companies developing new drugs.

We make sure to follow all rules by getting the necessary permits and approvals for importing and distributing controlled substances. Ikris verifies the authenticity and quality of the RLDs it sources by providing important certifications like Certificates of Analysis (COA), Batch Reports, and Certificates of Origin (COO). We also comply with WHO EU guidelines and regulations from the FDA and EMA.

From choosing products to delivering them, we maintain strict oversight to ensure the RLDs' authenticity and integrity, building trust with clients and regulatory bodies.

Conclusion:
Reliable sourcing and procurement of reference-listed drugs (RLDs) are vital for ensuring the quality and effectiveness of new generic medications. By sourcing RLDs from trusted suppliers in regions like France, Turkey, and Australia, pharmaceutical companies can meet regulatory requirements and support successful clinical trials. With Ikris Pharma Network (IPN) as your trusted clinical trial supplier, you can be confident in the authenticity and quality of the RLDs used in your drug development process.